Differential antibody responses to Plasmodium falciparum glycosylphosphatidylinositol anchors in patients with cerebral and mild malaria.

[1]  L. Marrama,et al.  Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. , 2005, Journal of Infectious Diseases.

[2]  E. Riley,et al.  Innate immunity to malaria , 2004, Nature Reviews Immunology.

[3]  L. Marrama,et al.  Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure. , 2003, The Journal of infectious diseases.

[4]  F. Nato,et al.  Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate. , 2003, Journal of molecular biology.

[5]  N. Anstey,et al.  Immunoglobulin G (IgG) responses to Plasmodium falciparum glycosylphosphatidylinositols are short-lived and predominantly of the IgG3 subclass. , 2003, The Journal of infectious diseases.

[6]  B. Beutler,et al.  Innate immune sensing and its roots: the story of endotoxin , 2003, Nature Reviews Immunology.

[7]  D. Gowda,et al.  Glucosamine Inhibits Inositol Acylation of the Glycosylphosphatidylinositol Anchors in IntraerythrocyticPlasmodium falciparum * , 2003, The Journal of Biological Chemistry.

[8]  G. Maguire,et al.  Antibodies to Plasmodium falciparum Glycosylphosphatidylinositols: Inverse Association with Tolerance of Parasitemia in Papua New Guinean Children and Adults , 2002, Infection and Immunity.

[9]  D. Kwiatkowski,et al.  Prevalence and Boosting of Antibodies to Plasmodium falciparum Glycosylphosphatidylinositols and Evaluation of Their Association with Protection from Mild and Severe Clinical Malaria , 2002, Infection and Immunity.

[10]  P. Seeberger,et al.  Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria , 2002, Nature.

[11]  J. Trape,et al.  Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite. , 2002, Microbes and infection.

[12]  D. Channe Gowda.  Structure and activity of glycosylphosphatidylinositol anchors of Plasmodium falciparum. , 2002, Microbes and infection.

[13]  A. Cowman,et al.  Antibodies against Merozoite Surface Protein (Msp)-119 Are a Major Component of the Invasion-Inhibitory Response in Individuals Immune to Malaria , 2001, The Journal of experimental medicine.

[14]  Catherine E. Costello,et al.  Glycosylphosphatidylinositol anchors of Plasmodium falciparum: molecular characterization and naturally elicited antibody response that may provide immunity to malaria pathogenesis. , 2000 .

[15]  O. Gaye,et al.  [Malaria in the central health district of Dakar (Senegal). Entomological, parasitological and clinical data]. , 2000, Sante.

[16]  R. Gazzinelli,et al.  Signaling of immune system cells by glycosylphosphatidylinositol (GPI) anchor and related structures derived from parasitic protozoa. , 2000, Current opinion in microbiology.

[17]  N. Day,et al.  The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. , 1999, The Journal of infectious diseases.

[18]  G. Bentley,et al.  The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate. , 1999, Molecular cell.

[19]  P. Gerold,et al.  Signal transduction in macrophages by glycosylphosphatidylinositols of Plasmodium, Trypanosoma, and Leishmania: activation of protein tyrosine kinases and protein kinase C by inositolglycan and diacylglycerol moieties. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Rogier,et al.  Combating malaria morbidity and mortality by reducing transmission. , 1996, Parasitology today.

[21]  P. Gerold,et al.  Glycosylphosphatidylinositol toxin of Plasmodium up-regulates intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin expression in vascular endothelial cells and increases leukocyte and parasite cytoadherence via tyrosine kinase-dependent signal transduction. , 1996, Journal of immunology.

[22]  A. Holder,et al.  Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. , 1996, The Journal of infectious diseases.

[23]  F. Hackett,et al.  Signal transduction in host cells by a glycosylphosphatidylinositol toxin of malaria parasites , 1993, The Journal of experimental medicine.

[24]  J. Trape,et al.  Vector density gradients and the epidemiology of urban malaria in Dakar, Senegal. , 1992, The American journal of tropical medicine and hygiene.

[25]  A. Holder,et al.  Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (Pf MSP1) of Plasmodium falciparum are associated with reduced malaria morbidity , 1992, Parasite immunology.

[26]  J. Playfair,et al.  The malaria vaccine: anti-parasite or anti-disease? , 1990, Immunology today.

[27]  A. Holder,et al.  The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor , 1984, The Journal of experimental medicine.